Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel R Denmeade

Showing results (91-100 of 155) with videos related to

Pageof 16
Sort By:
Anti-Cancer Drugs|June 22, 2007
Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicityRavibhushan Singh, Jeff L Browning, Ralph Abi-Habib, et al.
Cancer Research|September 23, 2003
CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growthChristopher J Strock, Jong-In Park, Mark Rosen, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 20, 2023
Liver Fibrosis Scores and Prostate Cancer Risk and Mortality in the Atherosclerosis Risk in Communities StudyAnqi Wang, Mariana Lazo, Jiayun Lu, et al.
The Prostate|September 2, 2014
Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancerRosa Nadal, Zhe Zhang, Hibba Rahman, et al.
Cancer Biology & Therapy|September 6, 2007
Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpointConnie Collins, Michael A Carducci, Mario A Eisenberger, et al.
Steroids|July 29, 2014
Targeting thapsigargin towards tumorsNhu Thi Quynh Doan, Eleonora Sandholdt Paulsen, Pankaj Sehgal, et al.
Investigational New Drugs|January 19, 2011
Synthesis and cytotoxic activities of some 2-arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell linesYakini Brandy, Innocent Ononiwu, Dolapo Adedeji, et al.
Urology|March 27, 2007
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapyGopal K Bajaj, Zhe Zhang, Elizabeth Garrett-Mayer, et al.
Phytochemistry|November 14, 2006
Cytotoxic phenylpropanoids and an additional thapsigargin analogue isolated from Thapsia garganicaHuizhen Liu, Kent Gunnertoft Jensen, Linh My Tran, et al.
Cancer Chemotherapy and Pharmacology|October 25, 2011
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trialEmmanuel S Antonarakis, Michael A Carducci, Mario A Eisenberger, et al.
Pageof 16

Showing results (91-100 of 155) with videos related to

Sort By:
Pageof 16
Anti-Cancer Drugs|June 22, 2007
Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicityRavibhushan Singh, Jeff L Browning, Ralph Abi-Habib, et al.
Cancer Research|September 23, 2003
CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growthChristopher J Strock, Jong-In Park, Mark Rosen, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 20, 2023
Liver Fibrosis Scores and Prostate Cancer Risk and Mortality in the Atherosclerosis Risk in Communities StudyAnqi Wang, Mariana Lazo, Jiayun Lu, et al.
The Prostate|September 2, 2014
Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancerRosa Nadal, Zhe Zhang, Hibba Rahman, et al.
Cancer Biology & Therapy|September 6, 2007
Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpointConnie Collins, Michael A Carducci, Mario A Eisenberger, et al.
Steroids|July 29, 2014
Targeting thapsigargin towards tumorsNhu Thi Quynh Doan, Eleonora Sandholdt Paulsen, Pankaj Sehgal, et al.
Investigational New Drugs|January 19, 2011
Synthesis and cytotoxic activities of some 2-arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell linesYakini Brandy, Innocent Ononiwu, Dolapo Adedeji, et al.
Urology|March 27, 2007
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapyGopal K Bajaj, Zhe Zhang, Elizabeth Garrett-Mayer, et al.
Phytochemistry|November 14, 2006
Cytotoxic phenylpropanoids and an additional thapsigargin analogue isolated from Thapsia garganicaHuizhen Liu, Kent Gunnertoft Jensen, Linh My Tran, et al.
Cancer Chemotherapy and Pharmacology|October 25, 2011
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trialEmmanuel S Antonarakis, Michael A Carducci, Mario A Eisenberger, et al.
Pageof 16